Navigation Links
Zargis Receives FDA Clearance for Signal X6 Telemedicine Device; OK Allows Delivery to US Army
Date:9/17/2009

STAMFORD, Conn., Sept. 17 /PRNewswire-FirstCall/ -- Zargis Medical Corp., a spin-off from Siemens Corporate Research (NYSE: SI) and a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), announced today it has received U.S. Food and Drug Administration (FDA) clearance to market its new Signal X6(TM) device. Zargis also announced the delivery of seven Signal X6 devices to the U.S. Army for deployment in six Department of Defense medical facilities.

Signal X6 is noninvasive, easy to use and simultaneously records heart and lung sounds from six adhesive sensors. The recordings can be evaluated locally or, for locations where a cardiac specialist is not immediately available for consultation, transmitted through the Internet for remote evaluation. Signal X6 and our recently launched Zargis Cardioscan(TM) device were both designed for user-friendly digital heart sound analysis. The configuration of the Signal X6 provides a unique telemedicine resource in situations where evaluations would benefit from high fidelity multi-channel synchronous recordings.

"As healthcare systems continue to demand improved outcomes with utilization of fewer resources, we believe that Signal X6 will provide cost-effective, high quality cardiac analysis in situations where it's not practical for a patient to visit a specialist," said John Kallassy, Zargis' CEO.

Prototypes for Signal X6 were first developed with funding from the Telemedicine and Advanced Technology Research Center (TATRC) through the AAMTI program. The AAMTI program provides funding to AMEDD personnel to demonstrate technology and document the impact on cost, access and quality of care. TATRC (www.tatrc.org) is an element of the United States Army Medical Research and Materiel Command (USAMRMC).

About Zargis Medical Corp.

Zargis Medical Corp. develops advanced diagnostic decision support products and services for primary care physicians, pediatricians, cardiologists and other healthcare professionals. Zargis was formed in 2001 when Siemens Corporate Research, a division of Siemens AG (NYSE: SI), and Speedus Corp. co-invested to develop and market an advanced acoustic technology designed to detect heart abnormalities identified through analysis of heart sounds.

For additional information about Zargis or Speedus Corp., contact Peter Hodge at 888.773.3669 (ext. 23) or phodge@zargis.com or visit the following Web sites: www.zargis.com and www.speedus.com.

Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts.


'/>"/>
SOURCE Speedus Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. 3M and Zargis Announce Global Marketing Alliance
2. Zargis Cardioscan(TM) Unveiled Through Global Marketing and Distribution Alliance With 3M Company
3. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
4. DaVita Receives Civil Complaint
5. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
6. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
7. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
8. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
9. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
10. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
11. Prime Therapeutics Receives TIPPS Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Indiana (PRWEB) , ... May 26, 2016 , ... ... provider of healthcare supply chain solutions, today announced the organization has earned its ... meets international standards and is compliant with all rules and policies associated with ...
(Date:5/26/2016)... Cypress, Texas (PRWEB) , ... May 26, 2016 , ... ... on Friday, May 13 at Blackhorse Golf Club in Cypress. With the help of ... a non-profit that restores, empowers, and renews hope for wounded service members and their ...
(Date:5/26/2016)... ... May 26, 2016 , ... The MIAMI Institute for Age ... speaker Dr. Adonis Maiquez MD, ABAARM. Dr. Adonis , Wellness Physician of the ... a member of the Institute for Functional Medicine. , He also heads up FITTLab, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the ... bunionette) treatment was more than humbled by customer demand over the Mother’s Day Weekend ... mid sale. Now that Bunion Bootie has completely replenished its inventory levels, it hopes ...
(Date:5/26/2016)... ... 26, 2016 , ... A health conscious snack that doesn't sacrifice taste? It's ... ignited an undeniable buzz in the protein product community by offering an alternative to ... doughnuts are packed with 11 grams of protein and made from a healthy blend ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... 2016  Zymo Research Corp. announced today the ... materials that help researchers obtain the most accurate ... The rapid growth of the study of microbiomes ... standard methods to improve the reproducibility and quality ... at every step of the measurement process including ...
(Date:5/25/2016)... As illustrated by the Spring ... the numbers and momentum of cannabis in the US ... billions, more research and development push the sector forward. ... Legal Marijuana Markets Report  from from ArcView Market Research ... the increase in sector is attributed to adult use ...
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
Breaking Medicine Technology: